Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Foeldvari

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Arthritis Research & Therapy|October 26, 2012
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementGerd Horneff, Sigrid Fitter, Ivan Foeldvari, et al.
European Journal of Pediatrics|May 6, 2018
Development of minimum standards of care for juvenile localized sclerodermaTamás Constantin, Ivan Foeldvari, Clare E Pain, et al.
The Journal of Rheumatology|May 5, 2007
Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, et al.
The Lancet. Rheumatology|March 5, 2026
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumabAthimalaipet V Ramanan, Nicolino Ruperto, Ivan Foeldvari, et al.
Annals of the Rheumatic Diseases|June 24, 2020
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialSeza Ozen, Eldad Ben-Cherit, Ivan Foeldvari, et al.
Rheumatology (Oxford, England)|October 12, 2022
Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survivalFranz Thiele, Ariane Klein, Jens Klotsche, et al.
RMD Open|October 25, 2022
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational studyLaura J Montag, Gerd Horneff, Paula Hoff, et al.
Arthritis Care & Research|July 26, 2018
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young AdulthoodKirsten Minden, Gerd Horneff, Martina Niewerth, et al.
The Journal of Rheumatology|November 18, 2008
A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritisIvan Foeldvari, Ilona S Szer, Lawrence S Zemel, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoringClare E Pain, Tamás Constantin, Natasa Toplak, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Arthritis Research & Therapy|October 26, 2012
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementGerd Horneff, Sigrid Fitter, Ivan Foeldvari, et al.
European Journal of Pediatrics|May 6, 2018
Development of minimum standards of care for juvenile localized sclerodermaTamás Constantin, Ivan Foeldvari, Clare E Pain, et al.
The Journal of Rheumatology|May 5, 2007
Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst, Dinesh Khanna, Marco Matucci-Cerinic, et al.
The Lancet. Rheumatology|March 5, 2026
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumabAthimalaipet V Ramanan, Nicolino Ruperto, Ivan Foeldvari, et al.
Annals of the Rheumatic Diseases|June 24, 2020
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialSeza Ozen, Eldad Ben-Cherit, Ivan Foeldvari, et al.
Rheumatology (Oxford, England)|October 12, 2022
Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survivalFranz Thiele, Ariane Klein, Jens Klotsche, et al.
RMD Open|October 25, 2022
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational studyLaura J Montag, Gerd Horneff, Paula Hoff, et al.
Arthritis Care & Research|July 26, 2018
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young AdulthoodKirsten Minden, Gerd Horneff, Martina Niewerth, et al.
The Journal of Rheumatology|November 18, 2008
A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritisIvan Foeldvari, Ilona S Szer, Lawrence S Zemel, et al.
Clinical and Experimental Rheumatology|August 6, 2016
Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoringClare E Pain, Tamás Constantin, Natasa Toplak, et al.
Pageof 18